Ameliorating effect of erythropoietin in a severe case of COVID-19: case report

Mais Mamoon Maufak, Gulfaraz Khan, Ani Purushothaman, Fiaz Ahamed, Mahir Khalil Jallo, Mohammed Rizwan, Sangeeth Kumar, Ahmed Almansouri, Taleb Mohamed Almansoori, Megha Thottappillil Ouseppachen

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


The COVID-19 pandemic is arguably one of the greatest public health crises since the 1918 influenza pandemic. Although several vaccines have been approved and rolled out, effective antiviral treatment options are very limited. Here, we present a case of severe COVID-19 that failed to respond to the standard interventions and continued to deteriorate. On day 22 of his illness, after informed consent, the patient was administered 4000IU of erythropoietin (EPO) subcutaneously, in the hope of improving his O2 saturation. Positive response was observed in the patient within 24 hours. This prompted us to continued EPO treatment for a total of 42 days until full recovery and discharge. Our findings warrant further studies to ascertain the use of EPO in severe cases COVID-19.

Original languageEnglish
Article number129
JournalPan African Medical Journal
Publication statusPublished - Sept 1 2022


  • COVID-19
  • Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
  • acute respiratory distress syndrome (ARDS)
  • case report
  • erythropoietin

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Ameliorating effect of erythropoietin in a severe case of COVID-19: case report'. Together they form a unique fingerprint.

Cite this